Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.

Article  PubMed  Google Scholar 

Feinberg AP, Levchenko A. Epigenetics as a mediator of plasticity in cancer. Science. 2023;379: eaaw3835.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yang GJ, Wu J, Miao L, Zhu MH, Zhou QJ, Lu XJ, et al. Pharmacological inhibition of KDM5A for cancer treatment. Eur J Med Chem. 2021;226:113855–71.

Article  CAS  PubMed  Google Scholar 

Hai R, Yang D, Zheng F, Wang W, Han X, Bode AM, et al. The emerging roles of HDACs and their therapeutic implications in cancer. Eur J Pharmacol. 2022;931:175216–31.

Article  CAS  PubMed  Google Scholar 

Nebbioso A, Carafa V, Conte M, Tambaro FP, Abbondanza C, Martens J, et al. c-Myc modulation and acetylation is a key HDAC inhibitor target in cancer. Clin Cancer Res. 2017;23:2542–55.

Article  CAS  PubMed  Google Scholar 

Zwergel C, Schnekenburger M, Sarno F, Battistelli C, Manara MC, Stazi G, et al. Identification of a novel quinoline-based DNA demethylating compound highly potent in cancer cells. Clin Epigenetics. 2019;11:68–85.

Article  PubMed  PubMed Central  Google Scholar 

Garcia-Martinez L, Zhang Y, Nakata Y, Chan HL, Morey L. Epigenetic mechanisms in breast cancer therapy and resistance. Nat Commun. 2021;12:1786–99.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gkountela S, Castro-Giner F, Szczerba BM, Vetter M, Landin J, Scherrer R, et al. Circulating tumor cell clustering shapes DNA methylation to enable metastasis seeding. Cell. 2019;176:98–e11214.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shah M, Cardenas R, Wang B, Persson J, Mongan NP, Grabowska A, et al. HOXC8 regulates self-renewal, differentiation and transformation of breast cancer stem cells. Mol Cancer. 2017;16:38.

Article  PubMed  PubMed Central  Google Scholar 

Panjarian S, Issa JJ. The roles of DNA demethylases in triple-negative breast cancer. Pharmaceuticals (Basel). 2021;14:628–41.

Article  CAS  PubMed  Google Scholar 

Ambatipudi S, Horvath S, Perrier F, Cuenin C, Hernandez-Vargas H, Le Calvez-Kelm F, et al. DNA methylome analysis identifies accelerated epigenetic ageing associated with postmenopausal breast cancer susceptibility. Eur J Cancer. 2017;75:299–307.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li S, Shen L, Chen KN. Association between H3K4 methylation and cancer prognosis: A meta-analysis. Thorac Cancer. 2018;9:794–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Benard A, Goossens-Beumer IJ, van Hoesel AQ, de Graaf W, Horati H, Putter H, et al. Histone trimethylation at H3K4, H3K9 and H4K20 correlates with patient survival and tumor recurrence in early-stage colon cancer. BMC Cancer. 2014;14:531.

Article  PubMed  PubMed Central  Google Scholar 

Fedele P, Orlando L, Cinieri S. Targeting triple negative breast cancer with histone deacetylase inhibitors. Expert Opin Investig Drugs. 2017;26:1199–206.

Article  CAS  PubMed  Google Scholar 

Mungamuri SK, Murk W, Grumolato L, Bernstein E, Aaronson SA. Chromatin modifications sequentially enhance ErbB2 expression in ErbB2-positive breast cancers. Cell Rep. 2013;5:302–13.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li CY, Liu YJ, Tao F, Chen RY, Shi JJ, Lu JF, et al. Lysine-specific demethylase 7A (KDM7A): A potential target for disease therapy. Biochem Pharmacol. 2023;216:115799.

Yang GJ, Liu YJ, Ding LJ, Tao F, Zhu MH, Shi ZY, et al. A state-of-the-art review on LSD1 and its inhibitors in breast cancer: Molecular mechanisms and therapeutic significance. Front Pharmacol. 2022;13:989575.

Yang G, Li C, Tao F, Liu Y, Zhu M, Du Y, et al. The emerging roles of lysine-specific demethylase 4A in cancer: Implications in tumorigenesis and therapeutic opportunities. Genes Dis. 2024;11:645–63.

Chen LJ, Xu XY, Zhong XD, Liu YJ, Zhu MH, Tao F, et al. The role of lysine-specific demethylase 6A (KDM6A) in tumorigenesis and its therapeutic potentials in cancer therapy. Bioorg Chem. 2023;133:106409.

Article  CAS  PubMed  Google Scholar 

Benedetti R, Dell’Aversana C, De Marchi T, Rotili D, Liu NQ, Novakovic B, et al. Inhibition of histone demethylases LSD1 and UTX regulates ERalpha signaling in breast cancer. Cancers (Basel). 2019;11:11122027–45.

Varghese B, Del Gaudio N, Cobellis G, Altucci L, Nebbioso A. KDM4 involvement in breast cancer and possible therapeutic approaches. Front Oncol. 2021;11:750315.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Walport LJ, Hopkinson RJ, Schofield CJ. Mechanisms of human histone and nucleic acid demethylases. Curr Opin Chem Biol. 2012;16:525–34.

Article  CAS  PubMed  Google Scholar 

Makki J. Diversity of breast carcinoma: histological subtypes and clinical relevance. Clin Med Insights Pathol. 2015;8:23–31.

Article  PubMed  PubMed Central  Google Scholar 

Meijnen P, Peterse JL, Antonini N, Rutgers EJ, van de Vijver MJ. Immunohistochemical categorisation of ductal carcinoma in situ of the breast. Br J Cancer. 2008;98:137–42.

Article  CAS  PubMed  Google Scholar 

Malhotra GK, Zhao X, Band H, Band V. Histological, molecular and functional subtypes of breast cancers. Cancer Biol Ther. 2010;10:955–60.

Article  PubMed  PubMed Central  Google Scholar 

Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001;98:10869–74.

Article  PubMed  PubMed Central  Google Scholar 

Cserni G. Histological type and typing of breast carcinomas and the WHO classification changes over time. Pathologica. 2020;112:25–41.

Article  PubMed  PubMed Central  Google Scholar 

Loibl S, Poortmans P, Morrow M, Denkert C, Curigliano G. Breast cancer. Lancet. 2021;397:1750–69.

Article  CAS  PubMed  Google Scholar 

Yersal O, Barutca S. Biological subtypes of breast cancer: Prognostic and therapeutic implications. World J Clin Oncol. 2014;5:412–24.

Article  PubMed  PubMed Central  Google Scholar 

Yin L, Duan JJ, Bian XW, Yu SC. Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res. 2020;22:61.

Article  PubMed  PubMed Central  Google Scholar 

Zhang L, Chen W, Liu S, Chen C. Targeting breast cancer stem cells. Int J Biol Sci. 2023;19:552–70.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Waks AG, Winer EP. Breast cancer treatment: a review. JAMA. 2019;321:288–300.

Article  CAS  PubMed  Google Scholar 

Chen MT, Sun HF, Zhao Y, Fu WY, Yang LP, Gao SP, et al. Comparison of patterns and prognosis among distant metastatic breast cancer patients by age groups: A SEER population-based analysis. Sci Rep. 2017;7:9254.

Article  PubMed  PubMed Central  Google Scholar 

Hollestelle A, Nagel JH, Smid M, Lam S, Elstrodt F, Wasielewski M, et al. Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines. Breast Cancer Res Treat. 2010;121:53–64.

Article  PubMed  Google Scholar 

Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell. 2006;10:515–27.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Riaz M, van Jaarsveld MT, Hollestelle A, Prager-van der Smissen WJ, Heine AA, Boersma AW, et al. miRNA expression profiling of 51 human breast cancer cell lines reveals subtype and driver mutation-specific miRNAs. Breast Cancer Res. 2013;15:R33.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Friese CR, Harrison JM, Janz NK, Jagsi R, Morrow M, Li Y, et al. Treatment-associated toxicities reported by patients with early-stage invasive breast cancer. Cancer. 2017;123:1925–34.

Article  PubMed  Google Scholar 

Korde LA, Somerfield MR, Carey LA, Crews JR, Denduluri N, Hwang ES, et al. Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO guideline. J Clin Oncol. 2021;39:1485–505.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Findlay M, von Minckwitz G, Wardley A. Effective oral chemotherapy for breast cancer: Pillars of strength. Ann Oncol. 2008;19:212–22.

Article